Chronic myelomonocytic leukemia with <i>NPM1</i> mutation or acute myeloid leukemia?

The 2022 WHO revision and the ICC classification have recently modified the diagnostic criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia. However, there is no consensus on whether CMML with NPM1 mutation (NPM1mut) should be diagnosed as AML. Nowadays, it is a subject of discussion because of its diagnostic and therapeutic implications. Therefore, we describe a case of a patient diagnosed with CMML NPM1mut and briefly review the literature to highlight the uncertainty about how to classify a CMML with NPM1 mutation. We emphasize the importance of a comprehensive molecular study, which is crucial to optimize the individualized treatment of patients, enabling them to access targeted therapies.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2024-09-30
DOI
https://doi.org/10.1093/oncolo/oyae246
Citations
2
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.91

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

Inés Zugasti, Francesca Guijarro, Sandra Castaño‐Díez, Marta Gómez‐Hernando et al.
2 citations
The Oncologist
Acute Myeloid Leukemia Research
0.91
article

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

Inés Zugasti, Francesca Guijarro, Sandra Castaño‐Díez, Marta Gómez‐Hernando, Mònica López‐Guerra, Daniel Esteban, Esther Carcelero, Ares Guardia, Jordi Esteve, Gisela Riu-Viladoms, Carlos Jiménez‐Vicente, Álex Bataller, Natalia Tovar, Ana Triguero, Irene López‐Oreja, Marı́a Rozman, Paola Charry, Dolors Costa, Marina Díaz‐Beyá, Sı́lvia Beà, Dolors Colomer, José Ramón Álamo Moreno, Albert Cortés‐Bullich, Daniel Munárriz, Víctor Torrecillas, Lucía Mont‐de Torres, Dolors Vela
article en
2 citations

Abstract

The 2022 WHO revision and the ICC classification have recently modified the diagnostic criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia. However, there is no consensus on whether CMML with NPM1 mutation (NPM1mut) should be diagnosed as AML. Nowadays, it is a subject of discussion because of its diagnostic and therapeutic implications. Therefore, we describe a case of a patient diagnosed with CMML NPM1mut and briefly review the literature to highlight the uncertainty about how to classify a CMML with NPM1 mutation. We emphasize the importance of a comprehensive molecular study, which is crucial to optimize the individualized treatment of patients, enabling them to access targeted therapies.

The OncologistVol. 30(2)
Josep Carreras Leukaemia Research Institute (ES), Hospital General de Granollers (ES), Hospital Clínic de Barcelona (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Universitat de Barcelona (ES)
European Commission, Instituto de Salud Carlos III
Good health and well-being
Openalex Percentile: Top 23%
Acute Myeloid Leukemia Research
0.91
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.